HATFIELD, England, April 6, 2016 /PRNewswire/ --

PRESS RELEASE NOT FOR SWISS OR AUSTRIAN MEDIA 

EMBARGOED UNTIL 00:01 GMT 6 April 2016  

Japanese research and development pharmaceutical company Eisai and PharmStandard, a leading Russian pharmaceutical company, today announce that they have signed Cooperation Agreements relating to the localised production of Eisai products in Russia. These agreements relate to Eisai's global oncology therapies, Halaven^® (eribulin) and Lenvima^® (lenvatinib), as well as the Company's global epilepsy therapy, Fycompa^® (perampanel).

Under the proposed agreements, important stages in the manufacturing process for both eribulin and lenvatinib will be completed in PharmStandard's cutting edge facilities in Ufa, while for perampanel these will be performed in PharmStandard's facility in Kursk.

Eribulin was registered in Russia in July 2012 and became accessible for patients with locally advanced or metastatic breast cancer who have progressed after at least one course of chemotherapy for advanced disease from September 2013. Lenvatinib was registered in Russia in December 2015 and will be accessible for treatment of radioactive iodine refractory differentiated thyroid cancer from June 2016. Perampanel was registered in August 2013 in Russia as adjunctive treatment for patients with partial onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older.

"This is an important step forward for the establishment of Eisai in Russia. Through this arrangement with PharmStandard, we can ensure that Russian patients will have access to our innovative drugs, eribulin, lenvatinib and perampanel. Our presence in Russia continues to grow and we are pleased to partner with this leading company to increase our value to patients and their families," comments Olga Konopleva, General Manager, Eisai Russia.

"We are pleased to partner with Eisai, one of the worldwide leaders in oncology and epilepsy, to expand the reach of their therapies and address patient needs in Russia," comments Grigory Potapov, CEO, "Pharmstandart PJSC"

This collaboration underscores Eisai's human health care (hhc) mission, the company's commitment to innovative solutions in disease prevention, cure and care for the health and well-being of people worldwide. Eisai is committed to epilepsy and oncology to address the unmet medical needs of patients and their families.

Notes to Editors 

About Eisai Co., Ltd. 

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With over 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realise our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Oncology and Neuroscience. 

As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit http://www.eisai.com

About PharmStandard 

PharmStandard is Russia's leading pharmaceutical company and develops and manufactures high-quality modern pharmaceutical products which meet the requirements of the healthcare system and the expectations of patients. PharmStandard manufactures more than 250 pharmaceutical products including drugs for treatments of cardio-vascular diseases, diabetes, growth hormone deficiency, gastroenterological, neurological, contagious diseases, metabolic disorders, cancer and other diseases. More than 120 PharmStandard products (taking into account all forms and dosages) are included in the list of Vital and Essential Pharmaceuticals.

As of 2004 PharmStandard developed more than 60 new pharmaceutical products in co-operation with Russia's leading scientific centres.

Date of preparation: March 2016

Job code: Corporate-UK2036

SOURCE Eisai